Insights

Innovative Vaccine Platform Glycovax Pharma's fully synthetic carbohydrate antigen technology offers a flexible and highly effective vaccine design platform, providing opportunities to collaborate with vaccine developers seeking cutting-edge solutions for infectious diseases and oncology.

Strategic Collaborations Recent partnerships with the National Research Council of Canada and the Université de Montréal demonstrate Glycovax's ability to engage with government and academic institutions, creating potential avenues for joint R&D projects and co-development opportunities.

Focus on Critical Diseases The company's focus on developing vaccines against Pseudomonas aeruginosa and other nosocomial infections positions it well to supply solutions to hospitals, healthcare providers, and pharmaceutical companies targeting urgent unmet medical needs.

Growing Market Engagement Participation in events like BIO International Convention signals Glycovax's intent to expand its network and establish strategic partnerships within the global biotech and pharmaceutical communities, ideal for sales outreach and business expansion.

Emerging Revenue Potential With current revenues under 1 million dollars but active development pipelines and recent licensing agreements, Glycovax presents opportunities for early-stage collaboration, licensing deals, and pilot projects with organizations seeking innovative vaccine solutions.

Similar companies to Glycovax Pharma

Glycovax Pharma Tech Stack

Glycovax Pharma uses 8 technology products and services including Cloudflare CDN, RSS, jQuery Migrate, and more. Explore Glycovax Pharma's tech stack below.

  • Cloudflare CDN
    Content Delivery Network
  • RSS
    Content Management System
  • jQuery Migrate
    Javascript Libraries
  • Google Maps
    Maps
  • Priority Hints
    Performance
  • Google Tag Manager
    Tag Management
  • Apache HTTP Server
    Web Servers
  • FitVids.js
    Web Tools And Plugins

Glycovax Pharma's Email Address Formats

Glycovax Pharma uses at least 1 format(s):
Glycovax Pharma Email FormatsExamplePercentage
FLast@glycovax.comJDoe@glycovax.com
47%
LastFirst@glycovax.comDoeJohn@glycovax.com
3%
FMiddleLast@glycovax.comJMichaelDoe@glycovax.com
3%
FLast@glycovax.comJDoe@glycovax.com
47%

Frequently Asked Questions

What is Glycovax Pharma's official website and social media links?

Minus sign iconPlus sign icon
Glycovax Pharma's official website is glycovax.com and has social profiles on LinkedInCrunchbase.

What is Glycovax Pharma's SIC code NAICS code?

Minus sign iconPlus sign icon
Glycovax Pharma's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Glycovax Pharma have currently?

Minus sign iconPlus sign icon
As of December 2025, Glycovax Pharma has approximately 13 employees across 1 continents, including North America. Key team members include Founder - Ceo: D. V.Vice-President Research: D. B.Scientific Director: S. M.. Explore Glycovax Pharma's employee directory with LeadIQ.

What industry does Glycovax Pharma belong to?

Minus sign iconPlus sign icon
Glycovax Pharma operates in the Biotechnology Research industry.

What technology does Glycovax Pharma use?

Minus sign iconPlus sign icon
Glycovax Pharma's tech stack includes Cloudflare CDNRSSjQuery MigrateGoogle MapsPriority HintsGoogle Tag ManagerApache HTTP ServerFitVids.js.

What is Glycovax Pharma's email format?

Minus sign iconPlus sign icon
Glycovax Pharma's email format typically follows the pattern of FLast@glycovax.com. Find more Glycovax Pharma email formats with LeadIQ.

When was Glycovax Pharma founded?

Minus sign iconPlus sign icon
Glycovax Pharma was founded in 2016.

Glycovax Pharma

Biotechnology ResearchQuebec, Canada11-50 Employees

Glycovax Pharma develops innovative carbohydrate-based vaccines to address critical health needs. We aim to deliver safe and effective solutions to empower vaccine developers as well as protect communities worldwide by fostering scientific excellence, collaboration and leveraging cutting-edge technology.

Glycovax is redefining capsular polysaccharide conjugate vaccine design to create the next generation of carbohydrate-based vaccines.
Our technology platform utilizes fully synthetic carbohydrate antigens, providing key advantages over natural antigens.
It combines a customizable linker, the CRM197 carrier protein, and a novel immunostimulating adjuvant to develop cutting-edge vaccines.
With unprecedented flexibility, this platform enables the design of vaccines with optimal reactivity and efficacy, addressing unmet medical needs in infectious diseases and oncology.

Glycovax Pharma développe des vaccins innovants à base d'hydrates de carbone pour répondre à des besoins de santé critiques. Notre objectif est de fournir des solutions sûres et efficaces pour permettre aux développeurs de vaccins de croître et pour protéger les communautés dans le monde entier, en encourageant l'excellence scientifique, la collaboration et l'utilisation de technologies de pointe.

Glycovax redéfinit la conception des vaccins conjugués à base de polysaccharides capsulaires pour créer la prochaine génération de vaccins à base d'hydrates de carbone.
Notre plateforme technologique utilise des antigènes glucidiques entièrement synthétiques, offrant des avantages clés par rapport aux antigènes naturels.
Elle associe un linker personnalisable, la protéine porteuse CRM197 et un nouvel adjuvant immunostimulant pour développer des vaccins de pointe.
Avec une flexibilité sans précédent, cette plateforme permet de concevoir des vaccins avec une réactivité et une efficacité optimales, répondant à des besoins médicaux non satisfaits dans les domaines des maladies infectieuses et de l'oncologie.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $1M

    Glycovax Pharma's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $1M

    Glycovax Pharma's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.